Ventripoint Diagnostics Closes $500,000 Private Placement
Toronto, Ontario -- March 21, 2025 -- NewsGenie -- Ventripoint Diagnostics Ltd. (TSXV:VPT) has finalized a non-brokered private placement, issuing 500 unsecured convertible debenture units for gross proceeds of $500,000. Each unit includes a $1,000 debenture, convertible into common shares at $0.14 per share, and 7,143 common share purchase warrants. Each warrant allows the holder to purchase a common share at $0.18 until June 28, 2027.
The debentures mature on June 28, 2027, and carry a 10% interest rate, payable semi-annually in cash or common shares. The Corporation paid $4,320 in finder’s fees and issued 30,857 finder’s warrants, each exercisable at $0.14 for 18 months.
Ventripoint plans to use the funds for sales and marketing, new personnel, and working capital. All securities are subject to a four-month hold period. The offering awaits final approval from the TSXV Venture Exchange.
Ventripoint is known for its AI-driven echocardiography solutions, offering accurate cardiac measurements comparable to MRI. Their VMS+ products work with various ultrasound systems and have regulatory approvals in the U.S., Europe, and Canada.
Hugh MacNaught can be contacted for further information at hmacnaught@ventripoint.com or 604-671-4201.